What is 4D Molecular Therapeutics's stock issuance proceeds?

4D Molecular Therapeutics (FDMT) reported stock issuance proceeds of $3.11M in Q1 2024.

How has 4D Molecular Therapeutics's stock issuance proceeds changed year-over-year?

4D Molecular Therapeutics's stock issuance proceeds increased by 119.8% year-over-year, from $1.42M to $3.11M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

4D Molecular Therapeutics FDMT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

EyePoint, Inc. EYPT

$166.79M+10.1%

RegenxbioRGNX

$146K-2.7%

MeiraGTx Holdings plcMGTX

$14.03M+213%

PVL

Palvella TherapeuticsPVLA

$230M—

Sarepta Therapeutics, Inc.SRPT

$241K-98.5%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 9, 2024, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's stock issuance proceeds?: 4D Molecular Therapeutics (FDMT) reported stock issuance proceeds of $3.11M in Q1 2024.
How has 4D Molecular Therapeutics's stock issuance proceeds changed year-over-year?: 4D Molecular Therapeutics's stock issuance proceeds increased by 119.8% year-over-year, from $1.42M to $3.11M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.